Assessment of safety, tolerability and blood concentrations of single doses of AZD3839 in healthy volunteers

Study identifier:D4080C00001

ClinicalTrials.gov identifier:N/A

EudraCT identifier:2011-001337-16

CTIS identifier:N/A

Study Complete

Official Title

A Phase I, Randomised, Double-blind, Placebo-controlled, Parallel-group Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Biomarkers of AZD3839 Including an Open-label Food Effect Group in Healthy Male and Female Volunteers of Non-childbearing Potential

Medical condition

Alzheimer's disease, Safety, Healthy Volunteers

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD3839, AZD3839 Placebo

Sex

All

Actual Enrollment

72

Study type

Interventional

Age

18 Years - 55 Years

Date

Study Start Date: 01 Jun 2011
Primary Completion Date: 01 Nov 2011
Study Completion Date: 01 Nov 2011

Study design

Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Basic Science

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria